Drugs / EntecaBell ODT. 0.5mg
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02588937 | Oct 2015 → Feb 2017 | chronic hepatitis B virus infection | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EntecaBell ODT. 0.5mg | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02588937 ↗ |